Key Takeaways
- Shares of Xenon Pharmaceuticals climbed 40% following successful Phase 3 X-TOLE2 trial results for azetukalner, which achieved its primary endpoint across both dosing cohorts.
- Patients receiving the 25 mg dosage experienced a 53.2% median reduction in monthly focal onset seizure frequency compared to baseline, versus just 10.4% in the placebo arm.
- The data surpassed the earlier Phase 2b X-TOLE trial, which demonstrated a 34.6% placebo-adjusted median percent reduction.
- More than half of participants (54.8%) in the 25 mg cohort achieved at least a 50% decrease in seizure frequency.
- The company intends to submit a New Drug Application (NDA) to the FDA during the third quarter of 2026.
Shares of Xenon Pharmaceuticals (XENE) jumped 40% during Monday’s trading session after the biotech company released positive Phase 3 X-TOLE2 trial data for azetukalner in patients with focal onset seizures. The impressive results exceeded market expectations, triggering a sharp rally in the stock price at market open.
Xenon Pharmaceuticals Inc., XENE
The clinical study included 380 adult patients suffering from highly refractory epilepsy. These participants had previously attempted a median of five different antiseizure medications and continued to experience approximately 12.75 seizures monthly at the study’s start.
Patients treated with the 25 mg dose of azetukalner demonstrated a median reduction of -53.2% in monthly focal onset seizure frequency from their baseline measurements. Meanwhile, the placebo cohort only saw a -10.4% reduction. This translates to a placebo-adjusted difference of -42.7%.
These figures are particularly significant. The previous Phase 2b X-TOLE trial had demonstrated a placebo-adjusted median percent reduction of -34.6% in the 25 mg cohort. The X-TOLE2 results substantially exceeded that benchmark.
The 15 mg dosage also delivered positive outcomes, achieving a -34.5% median percent reduction versus placebo, although the 25 mg data generated the most investor enthusiasm.
Key Secondary Measures Achieved
The study successfully met its primary secondary endpoint as well. Among patients in the 25 mg cohort, 54.8% experienced at least a 50% reduction in monthly seizure frequency — a metric called the Responder Rate 50. This compared favorably to only 20.8% in the placebo arm. The 15 mg cohort recorded a 37.6% responder rate.
Out of 332 participants who finished the double-blind phase, 322 continued into the open-label extension portion of the study.
The safety data remained consistent with earlier findings. The most frequently reported adverse events included dizziness, headache, somnolence, and fatigue. Discontinuation rates due to adverse events were 14.5% in the 25 mg cohort, 4.8% in the 15 mg cohort, and 3.2% in the placebo arm.
According to the company’s press release, Xenon CEO Ian Mortimer stated the findings demonstrated “the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study.”
Regulatory Path Forward
Xenon intends to file an NDA with the FDA for azetukalner as a treatment for focal onset seizures during Q3 2026. If granted approval, it would become the first KV7 potassium channel opener available commercially for epilepsy treatment.
Analysts at Stifel suggested the trial outcomes may prompt investors to increase their peak sales projections and market penetration forecasts for the medication.
Azetukalner offers several practical benefits compared to current treatment options — including once-daily administration, no titration requirements, and minimal drug-drug interactions.
The complete X-TOLE2 dataset will be shared during an oral presentation at the American Academy of Neurology (AAN) Annual Meeting scheduled for April.
Xenon is simultaneously advancing azetukalner for depression treatment, though that development program was not addressed in Monday’s announcement.
The stock traded approximately 40% higher as of Monday morning, with the rally entirely attributable to the Phase 3 data release.
